Abstract:Mitochondrial drug delivery has attracted increasing attention in various mitochondrial dysfunction-associated disorders such as cancer owing to the important role of energy production. Herein, we report a lysosomal pH-activated mitochondrial-targeting polymer nanoparticle to overcome drug resistance by a synergy between mitochondrial delivery of doxorubicin (DOX, an anticancer drug) and erlotinib-mediated inhibition of drug efflux. The obtained nanoparticles, DE-NPs could maintain negative charge and have long blood circulation while undergoing charge reversal at lysosomal pH after internalization by cancer cells. Thereafter, the acidity-activated polycationic and hydrophobic polypeptide domains boost lysosomal escape and mitochondrial-targeting drug delivery, leading to mitochondrial dysfunction, ATP suppression, and cell apoptosis. Moreover, the suppressed ATP supply and erlotinib enabled dual inhibition of drug efflux by DOX-resistant MCF-7/ADR cells, leading to significantly augmented intracellular DOX accumulation and a synergistic anticancer effect with a 17-fold decrease of IC50 relative to DOX. In vivo antitumor study demonstrates that DE-NPs efficiently suppressed the tumor burden in MCF-7/ADR tumor-bearing mice and led to negligible toxicity. This work establishes that a combination of mitochondrial drug delivery and drug efflux inhibition could be a promising strategy for combating multidrug resistance.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acsami.1c03196?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acsami.1c03196</a>.Synthetic scheme of PKCF; 1H NMR and FTIR spectra of polymers; DLS and zeta potentials of PKCF and D-NPs; cytotoxicity of PKCF NPs; cytotoxicity of Erlo and NPs against MCF-7 cells; cellular uptake of different formulations; cell cycle analysis; and H&E staining images of organs after treatment (<a class="ext-link" href="/doi/suppl/10.1021/acsami.1c03196/suppl_file/am1c03196_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

Mitochondrial-Targeting Lonidamine-Doxorubicin Nanoparticles for Synergistic Chemotherapy to Conquer Drug Resistance.

Polymer-lipid Hybrid Nanoparticles Synchronize Pharmacokinetics of Co-Encapsulated Doxorubicin-Mitomycin C and Enable Their Spatiotemporal Co-Delivery and Local Bioavailability in Breast Tumor.

A Mitochondria-Targeting Self-Assembled Carrier-Free Lonidamine Nanodrug for Redox-Activated Drug Release to Enhance Cancer Chemotherapy

Mitochondrial-targeting Nanoprodrugs to Mutually Reinforce Metabolic Inhibition and Autophagy for Combating Resistant Cancer.

Reversing Chemotherapy Resistance by a Synergy between Lysosomal pH-Activated Mitochondrial Drug Delivery and Erlotinib-Mediated Drug Efflux Inhibition

Co-delivery of Mitochondrial Targeted Lonidamine and PIN1 Inhibitor ATRA by Nanoparticulate Systems for Synergistic Metastasis Suppression

Mitochondria-targeting polydopamine-coated nanodrugs for effective photothermal- and chemo-synergistic therapies against lung cancer

Tumor acidity activated triphenylphosphonium-based mitochondrial targeting nanocarriers for overcoming drug resistance of cancer therapy

Mitochondrial Targeted Doxorubicin Derivatives Delivered by ROS-responsive Nanocarriers to Breast Tumor for Overcoming of Multidrug Resistance.

Dual Aptamer Modified Dendrigraft Poly-L-lysine Nanoparticles for Overcoming Multi-Drug Resistance Through Mitochondrial Targeting.

Mitochondrial Targeting and Ph-Responsive Nanogels for Co-Delivery of Lonidamine and Paclitaxel to Conquer Drug Resistance.

Mitochondria Apoptosis Pathway Synergistically Activated by Hierarchical Targeted Nanoparticles Co-Delivering Sirna and Lonidamine.

Mitochondria and Nucleus Dual Delivery System to Overcome DOX Resistance

Charge Reversible and Mitochondria/Nucleus Dual Target Lipid Hybrid Nanoparticles to Enhance Antitumor Activity of Doxorubicin.

Development of targeting lonidamine liposomes that circumvent drug-resistant cancer by acting on mitochondrial signaling pathways.

A Nanotheranostic System Combining Lysosomal Cell Death and Nuclear Apoptosis Functions for Synergistic Cancer Therapy and Addressing Drug Resistance

Mitochondrial Targeted Doxorubicin-Triphenylphosphonium Delivered by Hyaluronic Acid Modified and pH Responsive Nanocarriers to Breast Tumor: in Vitro and in Vivo Studies.

Trackable Mitochondria-Targeting Nanomicellar Loaded with Doxorubicin for Overcoming Drug Resistance

Tumor-Penetrating and Mitochondria-Targeted Drug Delivery Overcomes Doxorubicin Resistance in Lung Cancer

Overcoming Chemotherapy Resistance Via Simultaneous Drug-Efflux Circumvention and Mitochondrial Targeting

Mitochondria-Targeted Multifunctional Nanoprodrugs by Inhibiting Metabolic Reprogramming for Combating Cisplatin-Resistant Lung Cancer